Management of painful bone metastases

Current Opinion in Oncology

Volumn 19, Issue 4, 2007, Pages 308-314

  Mercadante, Sebastiano ^a   Fulfaro, Fabio ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Analgesics; Bisphosphonates; Bone pain; Metastatic bone disease; Radioisotopes; Radiotherapy

Indexed keywords

ANALGESIC AGENT; ANASTROZOLE; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; EXEMESTANE; FENTANYL; GONADORELIN ANTAGONIST; HYDROMORPHONE; IBANDRONIC ACID; LETROZOLE; LEXIDRONAM SAMARIUM SM 153; LOCAL ANESTHETIC AGENT; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PAMIDRONIC ACID; PENTETATE TIN 173M; PLACEBO; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALLODYNIA; ANALGESIA; BONE CANCER; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; COST CONTROL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG SUBSTITUTION; HORMONAL THERAPY; HUMAN; KYPHOPLASTY; MYELOMA; NEUROPATHIC PAIN; NEUTROPENIA; NOCICEPTION; OSTEOLYSIS; OSTEOSCLEROSIS; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANALGESICS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CALCITONIN; DIPHOSPHONATES; HUMANS; PAIN; RADIOISOTOPES; RADIOTHERAPY;

EID: 34250009724     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3281214400     Document Type: Review

References (73)

1. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997; 69:1-19.
2. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12:6243s-6249s. This is an excellent review of the natural history of metastatic bone disease, giving particular attention to skeletal complications.
3. Goblirsch MJ, Zwolak PP, Clohisy DR. Biology of bone cancer pain. Clin Cancer Res 2006; 12:6231s-6235s. The authors describe, in a very detailed manner, the pathophysiology of bone cancer pain.
4. Ripamonti C, Fulfaro F. Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 2000; 4:187-196.
5. Luger NM, Sabino M, Schwei MJ, et al. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs. inflammatory pain. Pain 2002; 99:397-406.
6. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain. Cancer 2002; 94:832-839.
7. Finniss DG, Benedetti F. Mechanisms of the placebo response and their impact on clinical trials and clinical practice. Pain 2005; 114:3-6.
8. Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res 2006; 12:6236s-6242s. A review of outstanding interest about pain measurement instruments.
9. Slatkin N. Cancer-related pain and its pharmacologic management in the patient with bone metastasis. J Support Oncol 2006; 4 (Suppl 1):15-21. This paper provides a comprhensive analysis of pharmacological management in patients with painful bone metastases.
10. O'Toole GC, Boland P. Metastatic bone cancer pain: etiology and treatment options. Curr Pain Headache Rep 2006; 10:288-292. An interesting review about treatment options in metastatic bone pain is presented.
11. Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004; 28:505-510.
12. Bruera E, Fainsinger R, MacEachern T, Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50:75-77.
13. Mercadante S, Bruera E. Opioid switching: a systemic and critical review. Cancer Treat Review 2006; 32:304-315.
14. Christie J, Simmonds M, Patt R, et al. Dose-titration multicenter study of transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998; 16:3238-3245.
15. Farrar J, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: a randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90:611-616.
16. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79:303-312.
17. Coluzzi P, Schwartzberg L, Conroy J, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain 2001; 91:123-130.
18. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebocontrolled study of fentanyl buccal tablet for breakthrough pain in opioidtreated patients with cancer. Clin J Pain 2006; 22:805-811.
19. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic-breakthrough pain, using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004; 27:352-359.
20. Caraceni A, De Conno F. Analgesic effects of chemotherapy? J Clin Oncol 1998; 16:803.
21. Perez EA. Appraising adjuvant aromatase inhibitor therapy. Oncologist 2006; 11:1058-1069.
22. Mottet N, Prayer-Galetti T, Hammerer P, et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006; 98:20-27.
23. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. Cancer Metastasis Rev 2006; 25:669-675. A complete and updated review of radiotherapy in the treatment of bone metastases is presented.
24. Janjan N. Palliation and supportive care in radiation medicine. Hematol Oncol Clin North Am 2006; 20:187-211. The author provides a comprehensive review outlining the role of radiation medicine in the palliation and supportive care of metastatic bone disease.
25. Agarawal JP, Swangsilpa T, van der Linden Y, et al. The role of external beam radiotherapy in the management of bone metastases. Clin Oncol (R Coll Radiol) 2006; 18:747-760. The authors provide an outstanding meta-analysis on use of radiotherapy in the management of bone metastases. It is of particular interest for clinicians because it is an evidence-based review.
26. Mercadante S. Scoring the effect of radiotherapy for painful bone metastases. Support Care Cancer 2006; 14:967-969.
27. Wu JS, Monk G, Clark T, et al. Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study. Clin Oncol (R Coll Radiol) 2006; 18:539-544. This interesting paper underscores the impact of radiotherapy on quality of life in patients with painful bone metastases.
28. Chow E, Ling A, Davis L, et al. Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases. Radiother Oncol 2005; 75:64-69.
29. Loblaw DA, Wu JS, Kirkbride P, et al. Pain flare in patients with bone metastases after palliative radiotherapy-a nested randomized control trial. Support Care Cancer 2006 [Epub ahead of print].
30. Shakespeare TP, Thiagarajan A, Gebski V, et al. Evaluation of quality of radiotherapy randomized trials for painful metastases. Cancer 2005; 103:1976-1981.
31. Wai MS, Mike S, Ines H, Malcolm M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy: a systematic review of the randomised trials. Cochrane Database Syst Rev 2004; 2:CD004721.
32. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97:798-804.
33. Kaasa S, Brenne E, Lund JA, et al. Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol 2006; 79:278-284. This is one of the most important studies in this field.
34. van der Linden YM, Steenland E, van Houwelingen HC, et al. Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother Oncol 2006; 78:245-253. Another critical study on this important issue is presented.
35. Chow E, Hoskin PJ, Wu J, et al. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Clin Oncol (R Coll Radiol) 2006; 18:125-128. This is a well conducted trial comparing two schedules of radiotherapy in the palliation of bone metastases.
36. Bradley NM, Husted J, Sey MS, et al. Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy. Support Care Cancer 2006 [Epub ahead of print].
37. Rades D, Veninga T, Stalpers LJ, et al. Outcome after radiotherapy alone for metastatic spinal cord compression in patients with oligometastases. J Clin Oncol 2007; 25:50-56.
38. Baumann G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastases: a systematic review. Radiother Oncol 2005; 75:258-270.
39. Liepe K, Runge R, Kotzerke J. Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 2005; 22:457-464.
40. Coronado M, Redondo A, Coya J, et al. Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med 2006; 31:605-610.
41. Brans B, Linden O, Giammarile F, et al. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006; 42:994-1003. An updated review about recent advances in the applications of newer radioisotopes is presented.
42. Minutoli F, Herberg A, Spadaro P, et al. (186)ReHEDP in the palliation of painful bone metastases from cancers other than prostate and breast. Q J Nucl Med Mol Imaging 2006; 50:355-362.
43. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005; 6:392-400.
44. Sartor O, Reid RH, Bushnell DL, et al. Safety and efficacy of repeat administration of Samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2006; 109:637-643.
45. Ripamonti C, Fagnoni E, Campa T, et al. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Support Care Cancer 2006 [Epub ahead of print].
46. Van der Poel HG, Antonini N, Hoefnagel CA, et al. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. Urol Int 2006; 77:50-56.
47. Nilsson S, Strang P, Ginman C, et al. Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. J Pain Symptom Manage 2005; 29:352-357.
48. Tu SM, Kim J, Pagliaro LC, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 2005; 23:7904-7910.
49. Storto G, Klain M, Paone G, et al. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006; 39:35-41. This is an interesting phase II trial of the combination of a radionuclide with a thirdgeneration bisphosphonate.
50. Ogawa K, Mukai T, Arano Y, et al. Rhemium-186- monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol 2006; 33:513-520.
51. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005; 23:8219-8224.
52. Body JJ. Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer 2006; 14:408-418. An excellent review about the use of bisphosphonates in metastatic bone disease is presented.
53. Halvorson KG, Sevcik MA, Ghilardi JR, et al. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin J Pain 2006; 22:587-600. This is an interesting analysis of physiopathology in different models of bone cancer.
54. Fulfaro F, Casuccio A, Ticozzi C, et al. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998; 78:157-169.
55. Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007; 4:42-55.
56. Furlow B. Zoledronic acid palliation in bone-metastatic breast cancer. Lancet Oncol 2006; 7:894.
57. Fulfaro F, Leto G, Badalamenti G, et al. The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 2005; 17:555-559.
58. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 24:4895-4900.
59. Cameron D, Fallon M, Diel I. Ibandronate: its role in metastatic breast cancer. Oncologist 2006; 11 (Suppl 1):27-33.
60. Pecherstorfer M, Rivkin S, Body JJ, et al. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Invest 2006; 26:315-322.
61. Tripathy D, Boby JJ, Bergstrom B. Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials. Clin Ther 2004; 26:1947-1959.
62. Kurth AA, Seraphin J, Schütze F, et al. Pain reduction with oral and intravenous ibandronate treatment for metastatic bone disease of breast cancer. Bone 2006; 38:77-78.
63. Vassiliou V, Kalogeropoulou C, Christopoulos C, et al. Combination ibandronate and radiotherapy for the treatment of bone metastases: Clinical evaluation and radiologic assessment. Int J Radiat Oncol Biol Phys 2007; 67:264-272.
64. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006; 17:1072-1082.
65. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005; 13:975-986.
66. Reed SD, Radeva JI, Glendenning GA, et al. Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. Am J Clin Oncol 2005; 28:8-16.
67. Martinez-Zapata MJ, Roque M, Alonso-Coello P, Catala E. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2006; 3:CD003223. This is an evidence-based review that identifies poor efficacy of calcitonin for metastatic bone pain.
68. Hollingworth W, Jarvik JG. Evidence on the effectiveness and cost-effectiveness of vertebroplasty: a review of policy makers' responses. Acad Radiol 2006; 13:50-55.
69. Barragan-Campos HM, Vallee JN, Lo D, et al. Percutaneous vertebroplasty for spinal metastases: complications. Radiology 2006; 238:354-362.
70. Cheung G, Chow E, Holden L, et al. Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: a prospective study using quality-of-life assessment. Can Assoc Radiol J 2006; 57:13-21.
71. Callstrom MR, Charboneau JW, Goetz MP, et al. Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. Radiology 2002; 224:87-97.
72. Catane R, Beck A, Inbar Y, et al. MR-guided focused ultrasound surgery (MRgFUS) for the palliation of pain in patients with bone metastases: preliminary clinical experience. Ann Oncol 2007; 18:163-167.
73. Callstrom MR, Atwell TD, Charboneau JW, et al. Painful metastases involving bone: percutaneous image-guided cryoablation: prospective trial interim analysis. Radiology 2006; 241:572-580.